Product Description
Mechanisms of Action: HSPE Inhibitor
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: Orphan Drug - Trypanosomiasis, African *
Approval Status: Not Approved
Approved Countries: Germany | India | Pakistan | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Optimum
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prostate Cancer
Phase 2: Glioblastoma|Brain Stem Cancer|Autism Spectrum Disorder|Adrenocortical Carcinoma|Plasmacytoma|Prostate Cancer|Breast Cancer|Multiple Myeloma|Castleman Disease|Renal Cell Carcinoma|Non-Small-Cell Lung Cancer|Acute Kidney Injury
Phase 1: Bladder Cancer|Transitional Cell Carcinoma|Hand, Foot and Mouth Disease|Non-Small-Cell Lung Cancer|Foot-and-Mouth Disease|Breast Cancer|Prostate Cancer|Colorectal Cancer|Adrenocortical Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2100042004 |
ChiCTR2100042004 | N/A |
Temporary halt |
COVID-19|Pneumonia |
2020-12-31 |
|||
ChiCTR2000030029 |
ChiCTR2000030029 | N/A |
Not yet recruiting |
COVID-19|Pneumonia |
2020-05-30 |
|||
NCT03804749 |
LC00-043 | P1 |
Unknown status |
Foot-and-Mouth Disease|Hand, Foot and Mouth Disease |
2019-12-19 |
50% |
2021-01-06 |
Primary Endpoints |
CTR20181965 |
CTR20181965 | P1 |
Completed |
Hand, Foot and Mouth Disease |
2019-09-06 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT00066768 |
NCI-2012-01440 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT00003038 |
CDR0000065661 | P1 |
Completed |
Prostate Cancer|Breast Cancer|Adrenocortical Carcinoma|Colorectal Cancer |
2003-01-01 |
2024-11-27 |
Treatments |
|
NCT00001381 |
94-C-0098 | P1 |
Completed |
Bladder Cancer|Transitional Cell Carcinoma |
None |
2019-03-21 |
||
NCT00006476 |
CRC-PHASE I/II-PH1/073 | P1 |
Completed |
Bladder Cancer |
None |
2019-03-21 |
Treatments |
|
NCT06866275 |
STAT-2A | P2 |
Recruiting |
Autism Spectrum Disorder |
2028-04-01 |
2% |
2025-05-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT04496596 |
RLS003-02-001 | P2 |
Unknown status |
Acute Kidney Injury |
2023-04-17 |
50% |
2025-05-03 |
Primary Endpoints|Treatments|Trial Status |
NCT06058962 |
PUR-ONQ-ASD-001 | P2 |
Completed |
Autism Spectrum Disorder |
2021-01-15 |
2024-06-26 |
Primary Endpoints|Treatments |
|
NCT02508259 |
SAT1 | P2 |
Completed |
Autism Spectrum Disorder |
2016-03-01 |
2019-08-10 |
Primary Endpoints |
|
NCT01671332 |
CO11508 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2015-06-11 |
2020-05-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01038752 |
Optimum-Suramin-1 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2012-11-01 |
2019-03-19 |
Treatments |
|
NCT00054028 |
NCI-2012-01431 | P2 |
Completed |
Breast Cancer |
2008-03-01 |
2020-10-26 |
Primary Endpoints |
|
NCT00006929 |
NCI-2012-01403 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2007-11-01 |
2019-03-21 |
Treatments |
|
NCT00083109 |
NCI-2012-02586 | P2 |
Completed |
Renal Cell Carcinoma |
2005-12-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
NCT00002921 |
CDR0000065324 | P2 |
Terminated |
Adrenocortical Carcinoma |
2004-01-01 |
2023-04-20 |
Primary Endpoints|Treatments |
|
NCT00004073 |
NABTT-9808 CDR0000067281 | P2 |
Completed |
Glioblastoma|Brain Stem Cancer |
2003-05-01 |
2019-03-21 |
Treatments |
|
NCT00002652 |
CDR0000064185 | P2 |
Completed |
Plasmacytoma|Multiple Myeloma|Castleman Disease |
None |
2019-03-21 |
Treatments |
|
NCT00002639 |
CDR0000064118 | P2 |
Completed |
Brain Stem Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00001266 |
91-C-0014 | P2 |
Completed |
Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00002723 |
NCI-2012-02788 | P3 |
Completed |
Prostate Cancer |
2002-08-01 |
2023-04-20 |
Primary Endpoints|Treatments |
|
NCT00002881 |
CDR0000065185 | P3 |
Completed |
Prostate Cancer |
1998-04-01 |
2023-04-20 |
Treatments |